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1  | INTRODUC TION
People with intellectual disabilities are more likely to experience 
poor health than the general population (Heslop et al., 2014; Krahn, 
Hammond, & Turner, 2006; van Schrojenstein Lantman‐de Valk & 
Walsh, 2008). Healthcare needs for people with intellectual disabilities 
can be complex, with a higher burden of multimorbidity and long‐term 
conditions such as epilepsy, psychosis, dementia and heart failure (Carey 
et al., 2016; Cooper et al., 2018; NHS Digital, 2016) and correspondingly 
greater medication use than in the general population (Doan, Lennox, 
Taylor‐Gomez, & Ware, 2013). However, there is limited research evi‐
dence about how people with intellectual disabilities understand their 
medication, and what support can be provided to maximize this.
Health service use is greater for people with intellectual disabil‐
ities compared to the general population, including a higher num‐
ber of primary care consultations per year (Carey et al., 2016) and 
a higher rate of hospital admissions (Dunn, Hughes‐McCormack, & 
Cooper, 2017; Glover & Evison, 2013), yet there is some evidence 
that healthcare providers may be less likely to follow best practice 
when treating people with intellectual disabilities (Dunn et al., 2017). 
Quality and Outcome Framework (QOF) indicators are used in the 
UK National Health Service (NHS), and they aim to measure out‐
comes that reflect the quality of healthcare (NHS Confederation, 
2018; NICE, 2019). Cooper et al. (2018) found that many QOF in‐
dicators were significantly less likely to be met in primary care for 
people with intellectual disabilities and long‐term conditions such 
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Abstract
Background: People with intellectual disabilities are more likely to experience poor 
health than the general population and are frequently prescribed multiple medica‐
tions. Therefore, it is important that people with intellectual disabilities understand 
their medication and potential adverse effects.
Method: A	scoping	review	explored	people	with	intellectual	disabilities’	knowledge	
of prescription medications, their risks and how medication understanding can be 
improved.
Results: Ten journal articles were included. People with intellectual disabilities often 
lacked understanding of their medication, including its name, purpose and when and 
how to take it. Participants were often confused or unaware of adverse effects asso‐
ciated with their medication. Information was sometimes explained to carers rather 
than people with intellectual disabilities. Some interventions and accessible informa‐
tion helped to improve knowledge in people with intellectual disabilities.
Conclusion: There is a need for accessible and tailored information about medication 
to be discussed with people with intellectual disabilities in order to meet legal and 
best practice standards.
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as epilepsy, diabetes and hypertension, compared to the general 
population. Compared to the general population with the relevant 
long‐term condition, this included fewer people with intellectual 
disabilities	 and	 diabetes	 having	 a	 HbA1C	 record	 in	 the	 previous	
15 months, and fewer people with asthma and intellectual disabil‐
ities having an asthma review in the previous 15 months.
An	effective	and	optimized	medication	regime	is	an	integral	part	
of managing health conditions. It is important for patients to under‐
stand the information about their medication to facilitate the man‐
agement	of	health	conditions.	As	part	of	 this,	effectively	 informing	
patients about the risks of adverse effects is essential for them to 
make informed decisions about their medicine‐taking and adhere to 
their treatment (Knapp, Raynor, & Berry, 2004). In the general pop‐
ulation, prescription medication instructions and warnings are often 
complex and, as a consequence, may not be fully understood resulting 
in misuse and adverse effects (Davis, Wolf, Bass, Middlebrooks, et al., 
2006; Davis, Wolf, Bass, Thompson, et al., 2006; Wolf, Davis, Shrank, 
Neuberger, & Parker, 2006; Wolf, Davis, Tilson, Bass, & Parker, 2006). 
In particular, studies have shown that people with low literacy levels 
often have difficulty both understanding and reading labels on med‐
ication (Davis, Wolf, Bass, Middlebrooks, et al., 2006; Wolf, Davis, 
Tilson, et al., 2006), which may predispose them to increased risk of 
experiencing adverse effects. The terms “adverse effects” and “side 
effects” of medicines are frequently used interchangeably. However, 
an “adverse effect” is an undesirable harmful effect resulting from a 
medicine, for example, ibuprofen increasing risk of peptic ulceration 
and olanzapine increasing the risk of constipation. Whereas a "side 
effect" is an effect secondary to the main or therapeutic effect of a 
medicine which may not necessarily be harmful and can be desirable 
in some circumstances. For the purposes of this scoping review, the 
present authors will refer to “adverse effects” with the exception of 
when reporting studies which have used different terminology.
There is often a high usage of prescription medications in people 
with intellectual disabilities. In a review of a general practice database, 
Straetmans, Schrojenstein Lantman‐de Valk, Schellevis, and Dinant 
(2007) found that prescription medications were received by 75% of 
people with intellectual disabilities compared to 59% of people with‐
out intellectual disabilities, and people with intellectual disabilities 
received 5.4 repeat prescriptions per year compared to 1.6 by those 
without intellectual disabilities. More recently, research has focused 
on the high levels of prescriptions of psychotropic medication for 
people with intellectual disabilities. Doan et al. (2013) found 35% of 
adults living with intellectual disabilities were prescribed psychotro‐
pic medications, mainly antipsychotics. In particular, studies suggest 
people with intellectual disabilities may be inappropriately prescribed 
psychotropic medication for the management of behaviours that 
challenge (Deb & Unwin, 2007; Holden & Gitlesen, 2004; Matson & 
Neal,	2009;	Sheehan	et	al.,	2015;	Singh	&	Matson,	2009).	A	UK	pop‐
ulation‐based cohort study reported that 49% of 33,016 people with 
intellectual disabilities were prescribed psychotropic medication yet 
only 21% had a record of mental illness and 25% had a record of chal‐
lenging behaviour (Sheehan et al., 2015). It has been estimated that, 
in England, up to 35,000 adults with intellectual disabilities are being 
prescribed a psychotropic medicine without appropriate clinical justi‐
fication (NHS England, 2018).
People with intellectual disabilities may be at increased risk of 
poor medication knowledge as they often experience additional 
challenges in health‐related communication due to factors including 
lack of accessible information, poor communication skills of health‐
care professionals and communication, and adaptive and cognitive 
difficulties associated with intellectual disabilities (Marks, Sisirak, 
&	 Hsieh,	 2008;	 Mastebroek,	 Naaldenberg,	 Lagro‐Janssen,	 &	 van	
Schrojenstein Lantman de Valk, 2014). Indeed, Strydom, Forster, 
Wilkie, Edwards, and Hall (2001) found that over half of people with 
intellectual disabilities interviewed were unable to read the label on 
their antipsychotic medicine and 86% did not know, or only knew 
one of, the adverse effects of their medication.
Patient‐centred practice is incorporated into guidelines for 
healthcare provision, including for people with intellectual disabili‐
ties. Patient‐centred practice aims to focus care on the needs of the 
person receiving the care rather than the needs of the service (Royal 
College of Nursing, 2016). The General Medical Council (GMC) is a 
body that sets standards for doctors in the UK and GMC guidance 
(c) emphasizes the importance of the doctor–patient relationship 
where a dialogue is created between the parties together with an 
exchange of views to enhance the patient's decision‐making process. 
All	organizations	providing	NHS	care	and/or	publicly	 funded	adult	
social	care	are	legally	required	to	follow	the	Accessible	Information	
Standard	 (AIS;NHS	 England,	 2016).	 This	 involves	 taking	 steps	 to	
ensure that the individual, including those with intellectual disabil‐
ities, receives information in an accessible format and receives any 
communication support they may need, and applies to discussions 
around medication (NHS England, 2017).
According	 to	 the	 Supreme	 Court	 case	 of	 Montgomery	 v	
Lanarkshire Health Board (Scotland) (2015), where a person has ca‐
pacity, healthcare professionals are under a duty “to take reasonable 
care to ensure that the patient is aware of any material risks involved 
in any recommended treatment, and of any reasonable alternative 
or variant” (para. 87). The judgement explains that a material risk is 
one that a “reasonable person in the patient's position” (para. 87) 
would consider significant or that the doctor is or should be aware 
that the patient would deem is significant (Barnett & Carr, 2018; 
Sokol, 2015). Where people with intellectual disabilities are con‐
cerned, the Montgomery case applies to those with mental capacity 
only, that is, able to make decisions for themselves about treatment. 
Therefore, the need to ensure that people with intellectual disabili‐
ties understand their medication, and its potential risks, is crucial in 
order to promote good health outcomes and to ensure that health‐
care providers are complying with legal requirements.
1.1 | Aims
Prescribed medications to manage health problems have the poten‐
tial	to	cause	short‐term	and	long‐term	adverse	effects.	An	individual	
with intellectual disabilities, just as those without intellectual disabili‐
ties, should be enabled to take an active part in the decision‐making 
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process. Empowering people with intellectual disabilities to be equal 
stakeholders in relation to their medicines and encouraging dialogue 
about medicines could lead to an improvement in therapeutic rela‐
tionships, better access to healthcare, improved adherence to phar‐
macological interventions and consequently a reduction in morbidity 
and	mortality	(Adams	&	Carr,	2017).	There	has	been	limited	research	
exploring the understanding of medication within the intellectual dis‐
ability population; therefore, this scoping review aimed to identify and 
analyse	 studies,	which	 explored	 people	with	 intellectual	 disabilities’	
understanding of prescription medications and the risks associated 
with these, along with how to improve understanding.
2  | METHODS
2.1 | Scoping review
Scoping reviews aim to map all of the relevant literature in a specific 
area of interest and consequently help to identify any gaps in exist‐
ing	research	 (Arksey	&	O'Malley,	2005).	This	approach	was	adopted	
as existing knowledge of the literature suggested a lack of previous re‐
search	exploring	people	with	intellectual	disabilities’	understanding	of	
risks associated with their prescription medication. This review utilized 
Arksey	and	O'Malley's	 (2005)	 framework	 for	 scoping	 reviews	which	
involves the following five stages: (1) identifying the research question; 
(2) identifying the relevant studies; (3) study selection; (4) charting the 
data; (5) collating, summarizing and reporting the results.
2.2 | Stage 1: Identifying the research question
Three research questions directed this scoping review to address 
current gaps in the literature:
1. What understanding do people with intellectual disabilities have 
of their prescription medications?
2. What understanding do people with intellectual disabilities have 
of the risks (i.e., risk of an adverse effect) associated with their 
prescription medications?
3.	 How	 can	 people	 with	 intellectual	 disabilities’	 understanding	 of	
prescription medication be improved?
2.3 | Stage 2: Identifying relevant studies
Between	 the	 18	 and	 20	 January	 2017,	 searches	 of	 the	 following	
electronic	 databases	 were	 carried	 out;	 PubMed,	 Scopus,	 CINAHL,	
OpenGrey, the Cochrane database of systematic reviews and Web 
of Science. The search was repeated on 9 May 2018 to search the 
databases	 for	 papers	 published	 between	 1	 January	 2017	 and	 31	
December	 2017.	 Additionally,	 references	 from	 the	 identified	 ar‐
ticles	were	screened	to	 identify	any	 further	 relevant	material.	As	a	
result	 of	 the	 June	 2011	Panorama	 exposure	 of	 the	 ongoing	 abuse	
at Winterbourne View, practice and policy regarding intellectual 
disabilities	 are	 changing.	At	Winterbourne	View,	 a	 private	 hospital	
in England, it was found that staff routinely mistreated and abused 
people with intellectual disabilities in their care, leading to criminal 
convictions. In December 2012, the Department of Health (2012) 
Review	“Transforming	Care:	A	National	Response	 to	Winterbourne	
View Hospital” recommended that people with intellectual disabili‐
ties should be supported in community settings and not in long‐stay 
hospitals. Following concerns regarding the overuse of psychotropic 
medicines, it is recommended that medication is frequently reviewed 
by the healthcare team. These changes together with the strong 
focus on person‐centred care, planning and advocacy have led to a 
shift in policy regarding supporting people with intellectual disabili‐
ties (Department of Health, 2012). Literature published prior to 2011, 
therefore, may not be relevant to current practice and so this scoping 
review only included literature published from 2011 onwards. Further 
details regarding the search terms used are provided in Table 1.
2.4 | Stage 3: Study selection
Studies were included if they (a) reported on people with intellectual 
disabilities’	understanding	of	prescription	medication	from	the	per‐
spective of people with intellectual disabilities or others (e.g., fam‐
ily members, paid caregivers) or (b) aimed to improve people with 
Search term 1 Search term 2 Search term 3
Search operator AND AND
Intellectual disability Medications Side effects
Learning disability Prescriptions Risks
Learning disorders Drugs Knowledge
Learning difficulties Pharmaceutical preparations Understanding
 Prescription Decision making
 Medicine Consent
 Medicines Information
 Pharmacological interventions Informed consent
  Health education
  Health literacy
  Adverse	effects
TA B L E  1   Search terms
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intellectual	 disabilities’	 understanding	 of	 prescription	 medication.	
The search was restricted to published and peer‐reviewed journals 
and studies were included if published between 2011 and 2017.
Studies were excluded from this scoping review if they met any 
of the following criteria:
1. only reported understanding of non‐medication treatments such 
as surgery or psychological therapy
2. were not written in the English language (due to the time and cost 
involved in translating them to English)
3. only reported the medication knowledge of family or paid carers
4. were an animal study
5. were a review article.
Retrieved records from the database searches were extracted 
and imported in to EndNote, where duplicates were removed. Two 
researchers independently screened the titles and abstracts based 
on the inclusion/exclusion criteria described earlier. Following the 
initial screening, full‐text articles were read by both reviewers to 
make	a	final	decision	of	inclusion.	Any	disagreements	about	the	in‐
clusion of the articles were resolved by discussion with a third mem‐
ber of the research team. The reference lists of all included articles 
and all excluded relevant review articles were examined to ensure 
that all relevant and eligible studies had been identified.
2.5 | Stage 4: Charting the data
A	data	extraction	sheet	was	developed	in	Excel,	and	relevant	articles	
were charted using the following column headings:
1.	 Author(s),	 year	 of	 publication,	 study	 location
2. Type of publication and study
3. Main purpose of study
4. Methodological approach
5. Participant characteristics and sample size
6. Methodology
7. Setting
8. Intervention (if applicable)
9. Data collection and data analysis
10. Main findings.
Two researchers piloted the data extraction chart on one study and 
one of the researchers independently extracted data from each of the 
remaining studies.
2.6 | Stage 5: Collating, summarizing and 
reporting the results
All	extracted	data	from	the	included	articles	were	summarized	and	
tabulated	by	a	member	of	the	research	team.	In	line	with	Arksey	and	
O'Malley (2005), we presented our narrative account in two ways. 
Firstly, we reported the nature and distribution of the studies in‐
cluded, for example study design, country, settings and participant 
group. Secondly, we organized the literature according to the follow‐
ing themes which were drawn from the research questions: under‐
standing of prescription medications, understanding of prescription 
medication risks and how to improve understanding of prescription 
medication in people with intellectual disabilities.
3  | RESULTS
3.1 | Included studies
The searches in 2017 and 2018 are presented together as the search 
methodology was the same. Initial searching of the aforementioned 
electronic databases provided 1,326 records. Four hundred and four 
duplicates were removed leaving 922 records to screen for relevance 
based on title and abstract. Based on title and abstract screening, 
886 records were excluded. Thirty‐six full‐text articles were re‐
trieved and assessed by the researchers for inclusion. Twenty‐seven 
studies	were	excluded.	A	total	of	nine	studies	met	all	 inclusion	cri‐
teria and were subsequently included in the review. When screen‐
ing the references of the nine included studies, one article (Dysch, 
Chung, & Fox, 2012) was found to fit the inclusion criteria and was 
therefore	also	included	within	the	review.	An	overview	of	the	study	
selection process is provided in Figure 1.
3.2 | Study characteristics
All	 identified	articles	 reported	completed	studies.	Characteristics	of	
the included articles are summarized in Table 2. Study designs included 
a medical records search (Davis et al., 2014), quantitative studies 
(Beacroft & Dodd, 2010; Huneke, Gupta, Halder, & Chaudhry, 2012), 
qualitative studies (Davis et al., 2016; Dysch et al., 2012; Fish, Hatton, & 
Chauhan, 2017; Walmsley et al., 2016), a case study (Flood & Henman, 
2015) and two pre‐/post‐test interventions (Ferguson & Murphy, 
2014; Sheehan, Rochester, Hafesji, Kyambadde, & Gravestock, 2017). 
The intervention in Ferguson and Murphy's study consisted of three 
training sessions including information on the function of medication, 
possible side effects, risks, benefits and alternatives to medication. 
Sheehan	et	al.’s	intervention	was	a	psychotropic	medication	education	
group that took place once a week for eight weeks discussing indi‐
cations, how medication could help, possible side effects and how to 
manage them, and where to seek further information.
Of the included articles, eight were conducted in the United 
Kingdom (Beacroft & Dodd, 2010; Dysch et al., 2012; Ferguson & 
Murphy, 2014; Fish et al., 2017; Flood & Henman, 2015; Huneke et 
al., 2012; Sheehan et al., 2017; Walmsley et al., 2016) and two in 
Australia	 (Davis	et	al.,	2016,	2014).	All	 ten	articles	had	been	com‐
pleted and published.
3.2.1 | Participants
All	articles	discussed	adults	(18+)	with	intellectual	disabilities.	Data	
were collected from participants with intellectual disabilities and 
asthma in two of the included studies (Davis et al., 2016, 2014). 
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Two studies involved participants with intellectual disabilities and 
diabetes (Dysch et al.,  2012; Flood & Henman, 2015). One study 
interviewed females with intellectual disabilities who were using, 
intended to or had used contraception (Walmsley et al., 2016). The 
other five studies included in this scoping review were not con‐
strained to a particular condition (Beacroft & Dodd, 2010; Ferguson 
& Murphy, 2014; Fish et al., 2017; Huneke et al., 2012; Sheehan 
et al., 2017). The studies were conducted in a range of settings in‐
cluding day services and supported living (Beacroft & Dodd, 2010; 
Huneke et al., 2012), secure psychiatry wards (Sheehan et al., 2017) 
and a self‐advocacy conference (Fish et al., 2017).
3.3 | Knowledge of prescription medications
There was a range of findings about the medication knowledge of 
people with intellectual disabilities, but the majority of articles found 
evidence that many people with intellectual disabilities did not fully 
understand their prescription medication, including medication 
names, its purpose, when and how to take it and how to store it.
3.3.1 | Purpose of medication
Two of the included articles presented findings showing good levels 
of knowledge amongst people with intellectual disabilities regard‐
ing prescription medication, including what medication they were 
taking	 and	 why.	 Participants	 in	 Sheehan	 et	 al.’s	 (2017)	 education	
study rated their knowledge of and comfort with medication be‐
fore and after participating in a psychotropic medication education 
group.	At	 baseline	 and	post‐intervention,	 all	 participants	 reported	
strongly agreeing with knowing enough about their medication and 
that medication is an important part of their treatment.
Davis et al. (2016) carried out 17 semi‐structured interviews to 
explore the level of understanding of prescription inhalers in people 
with intellectual disabilities and asthma. They found that most par‐
ticipants were aware of their diagnosis and what their medication 
did for them, for example, “relax the airway when it's wheezy.” Most 
participants were also able to link not taking medication to negative 
health consequences, for example, “if I don't take that, I feel a bit 
funny	when	I	start	walking.	I	get	choked	up	a	bit,”	“if	I	didn't	use	it	I’d	
probably be in hospital” and “if I don't take this one, I get sick.”
Two studies found more variable medication knowledge, but with 
some	notable	cases	of	good	understanding.	 In	Dysch	et	al.’s	 (2012)	
study, one participant expressed an understanding of diabetes med‐
ication “so they have insulin injections to actually um, grasp more in‐
sulin inside themselves” and one participant was able to identify early 
warning signs that she had not taken her medication “I can tell when 
I’ve	not	had	the	tablets	and	stuff.	Sometimes	I	feel	hungry	or	empty.	
And	I’ve	got	to	have	something	to	make	myself	well.”	Some	partici‐
pants expressed understanding the consequences of not taking their 
medication “I know the consequences…where you might lose a limb 
F I G U R E  1   Flow chart of studies from 
identification to inclusion
6  |    
Published for the British Institute of Learning Disabilities  
SMITH eT al.
or something like that, which people could do if they don't take their 
medication	properly”	 and	 “I	 know	 I’ve	got	 to	do	 it	 to	 save	my	 life.”	
Walmsley et al. (2016) found that of the 19 women with intellectual 
disabilities they interviewed about contraception use, two women 
were well informed, with one expressing knowledge of when you 
should be on contraception and how to get it “if you are in a relation‐
ship, you see a specialist, get sensible contraception advice and also 
talk to a specialist about the right contraception with your doctor….”
TA B L E  2   Overview of medication knowledge amongst people with intellectual disabilities
Author, 
year Study design Study aim(s) Participants Methodology Findings
Beacroft 
& Dodd, 
2010
Audit	using	
interviews
To investigate 
pain recognition 
and manage‐
ment in people 
with intellectual 
disabilities
N = 40; people aged 
18 and over with 
mild–moderate in‐
tellectual disabilities 
with good verbal 
abilities (as rated by 
service manager)
Interviews structured by 
a 40‐item questionnaire 
containing both open and 
closed questions with sec‐
tions on views about pain 
medication
• 30% would not take medicine 
if in pain, and when asked why, 
there was confusion and concern 
around whether the pain medica‐
tion would react badly with their 
regular medication
• 18 participants (45%) did not 
know what medication they took
Davis et 
al., 2014
Retrospective 
medical 
record audit
To describe 
respiratory 
medication use, 
prevalence of 
asthma and 
asthma manage‐
ment practices
N = 125; accessible 
records for patients 
(aged	18+)	with	in‐
tellectual disabilities 
and asthma whom 
attended a special‐
ized	Australian	
clinic. 107 of which 
were prescribed 
asthma medications
Electronic and hard copy 
health records were 
analysed quantitatively and 
qualitatively including con‐
tent analysis of comments 
regarding use of respiratory 
medications from the hard 
copy records to identify any 
issues relating to inhalers
• Inhaler use was identified as 
an issue, particularly inhaler 
technique
• Respiratory physicians, asthma 
educators, GPs and pharmacists 
were identified as important in 
training people with intellectual 
disabilities in inhaler use
•	 Ability	to	use	inhalers	was	not	
reported for all participants. 
Where this was commented on, 
records showed one patient was 
unsure how to use their inhaler, 
and other patients were noted 
to want advice on inhaler use or 
need constant reminding to use 
their inhaler
Davis et 
al., 2016
Qualitative 
study
To explore the 
level of un‐
derstanding of 
inhaled asthma 
medication use 
of people with 
intellectual 
disabilities, in 
the context of 
asthma self‐
management
N = 17; adults with 
intellectual disabili‐
ties, diagnosed with 
asthma and who 
self‐administered 
asthma medication
Semi‐structured face‐to‐face 
interviews based on the‐
matic framework approach 
including questions about 
understanding asthma 
medications.
• Three themes emerged:
o understanding of their illness 
and need for medication
o self‐management
o autonomy versus dependence
• Participants showed an awareness 
of their diagnosis and what their 
different medications did
• Most participants related not 
using medication to negative 
health consequences such as 
hospitalization and difficulty 
breathing
•	 A	majority	of	participants	did	not	
know what the potential risks or 
side effects of inhalers were
Dysch et 
al., 2012
Qualitative 
study
To explore the 
subjective 
experiences 
and perceptions 
of people with 
intellectual 
disabilities and 
diabetes
N	=	4;	Adults	(18+)	
with mild intellectual 
disabilities, capacity 
to consent and with 
a diagnosis of type 1 
or 2 diabetes
Semi‐structured interviews 
including questions about 
perceptions of health and 
being healthy, what diabe‐
tes meant to the person, 
how it affected their life, 
received support and what 
they thought might happen 
in the future.
• Participants could use language 
associated with their illness, which 
was interpreted as showing under‐
standing of diabetes
• One participant stated knowing 
the consequences of not taking 
their medication properly
• When discussing administer‐
ing medication by injection, one 
participant	stated	“I	know	I’ve	got	
to do it so save my life”
(Continues)
     |  7
Published for the British Institute of Learning Disabilities  
SMITH eT al.
Author, 
year Study design Study aim(s) Participants Methodology Findings
Ferguson 
& 
Murphy, 
2014
Pre‐/post‐test 
intervention
To investigate 
the capacity 
of people with 
intellectual dis‐
abilities to make 
decisions about 
their medication 
and to evalu‐
ate whether 
the provision 
of medica‐
tion training 
sessions would 
increase this 
capacity
N	=	28;	adults	(18+)	
with mild to moder‐
ate intellectual 
disabilities currently 
taking metformin, 
haloperidol or 
sodium valproate 
medications or on 
multiple medications
Participants were split into 
groups depending on medi‐
cation and all received three 
training sessions tailored 
to their medications. The 
Adapted	Assessment	of	
Capacity	Questionnaire	(A‐
ACQ)	was	adapted	to	focus	
on medication taking. The 
adapted	A‐ACQ	and	British	
Picture Vocabulary Scale‐II 
(BVPS‐II; assesses language 
comprehension) measures 
were taken at baseline, pre‐ 
and post‐intervention
• Highly significant positive correla‐
tions between the BPVS‐II scores 
and	A‐ACQ	scores	at	baseline	
assessment, suggesting a relation‐
ship between verbal ability and 
capacity
•	 The	A‐ACQ	scores	increased	
significantly following the 
intervention
Fish et al., 
2017
Mixed‐meth‐
ods study 
using ques‐
tionnaires
To gauge the level 
of information 
currently being 
provided to peo‐
ple with intellec‐
tual disabilities 
from their GP 
and pharmacist 
about medica‐
tions, and the 
requirements 
of people with 
intellectual 
disabilities for 
information 
related to their 
medication
N = 58; intellectual 
disabilities self‐ad‐
vocates at the North 
West	Self‐Advocacy	
conference
Easy‐read questionnaire 
(accompanied by pictures) 
completed by people with 
intellectual disabilities 
to explore their views on 
information given by health 
care professionals regarding 
medication
• The most frequent themes were 
that the information was not 
always accessible to participants.
• 24% reported receiving no infor‐
mation regarding medication at all
• When information was provided, 
it was instructional, for example, 
dosage and when to take the 
medicine
• 66% of people wanted easy‐
read leaflets and 17% wanted 
pictures or diagrams to present 
information
Flood & 
Henman, 
2015
Case study 
using an 
interview 
and medi‐
cal record 
review
To determine 
the views and 
knowledge of 
a person with 
intellectual dis‐
abilities about 
medication use
N = 1; a man with 
mild intellectual 
disabilities and dia‐
betes aged between 
30 and 40 years
Interview analysed with 
a Grounded Theory ap‐
proach. The participant's 
medication items were also 
reviewed
• The participant appeared to be 
responsible for his own diabetes 
self‐care.
• He described how he administered 
insulin and took his tablets only 
because he does not “want to die”
Huneke et 
al., 2012
Quantitative 
audit using 
question‐
naires
To evaluate cur‐
rent practice 
concerning con‐
sent to treat‐
ment in patients 
with intellectual 
disabilities 
against best 
practice guide‐
lines and to see 
whether these 
patients are 
given enough 
understandable 
information, to 
make informed 
decisions about 
their medication
N = 45; adult patients 
with intellectual 
disabilities living in 
supported accom‐
modation. Eight had 
capacity to consent. 
medical treatment 
according to staff
Participants received easy‐
read format questionnaires 
via post and, with the help 
of their support worker 
were asked to complete and 
return the survey The ques‐
tionnaires included Picture 
Communication Symbols 
(PCS),	assessing	patients’	
knowledge regarding their 
medication including pos‐
sible adverse effects and 
consequences of not taking 
the medication. Patients' 
medication knowledge was 
calculated
• Those with capacity showed good 
knowledge of the purpose of 
their medication, dose schedule, 
advantages of the treatment, and 
consequences of not taking the 
medication and contraindicated 
foods and drinks
• Participants with capacity had 
poor knowledge of the proposed 
duration of their treatment and 
the possible disadvantages and 
names of their medications
• Those without capacity had 
less knowledge of medications 
than those identified as having 
capacity. Knowledge of medica‐
tion names, duration of treatment 
and possible disadvantages were 
particularly poor
TA B L E  2   Continued
(Continues)
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The 19 participants in Walmsley et al. (2016) were all using, in‐
tending to or had used contraception in the past, yet in some cases 
there was little knowledge and understanding about what contra‐
ception was and why it would be used, for example, when asked 
“contraception—do you know what it means?” one participant 
responded “your health? No, not much.” The authors report that 
several participants also appeared to have no understanding of con‐
traception as a pregnancy preventative.
Beacroft and Dodd's study (2010) found poor knowledge of the 
purpose of medication. They found eighteen of 40 participants (45%) 
did not know what medication they took and although 53% reported 
that they knew why they were taking prescription medications, they 
did not know the name of their medication(s). The majority of people 
with intellectual disabilities were happy to take medication for their 
pain when given to them by staff, but only 18% stated they would 
take medicine if they were in pain when alone at home, suggesting 
that independent use of medication was low.
3.3.2 | Use of medication
Along	 with	 exploring	 people	 with	 intellectual	 disabilities’	 under‐
standing of what medication they take and why, three studies ex‐
plored understanding about how medication should be used. Davis 
et al. (2014) presented six comments from clinic doctors regard‐
ing inhaler use written during clinic attendance for patients with 
asthma.	 All	 comments	 indicated	 that	 the	 patients	 lacked	 knowl‐
edge regarding their asthma prescription medication. One pa‐
tient stated being “unsure how to use puffer” and another “uses 
inhaler without spacer; needs constant reminding.” However, only 
six comments were presented out of the 125 available asthma re‐
cords (hard copy) for people with asthma and intellectual disabili‐
ties so an assumption cannot be made that the lack of knowledge 
was evident across all patients. Davis et al. (2016) extended these 
findings by asking people with intellectual disabilities about their 
use	of	asthma	medication.	Although	the	 interviews	 indicated	that	
some participants had not been shown how to use their prescribed 
inhaler, others were knowledgeable about using different inhalers 
in	different	situations,	for	example,	“this	one	I	have	if	I’m	short	of	
breath,” and appeared to understand the significance of using their 
inhaled medications.
Flood and Henman (2015) conducted a case study with one man 
with mild intellectual disabilities and diabetes aged between 30 and 
40	 years.	 Although	 the	 participant	 appeared	 to	 understand	 what	
medication he was on and was able to describe how he administers 
his insulin, he did not store some of his medication (insulin or gluca‐
gon)	according	to	the	manufacturers’	directions.
Author, 
year Study design Study aim(s) Participants Methodology Findings
Sheehan 
et al., 
2017
Pre‐/post‐test 
intervention
To establish 
and evaluate a 
psychotropic 
medication 
education group 
for men with 
intellectual 
disability on a 
secure psychiat‐
ric ward
N = 6; men with intel‐
lectual disabilities on 
a secure psychiatric 
ward with a range of 
psychiatric diagno‐
ses at various stages 
of recovery
People with intellectual 
disabilities participated in 
a psychotropic medica‐
tion education group, once 
weekly over 8 weeks. 
Knowledge and confidence 
with prescribed medica‐
tion were assessed by 
self‐report and by a test of 
medication knowledge (20 
true or false statements) 
pre‐ and post‐ intervention
• There was no statistically signifi‐
cant difference between pre‐ and 
post‐group scores in the psycho‐
tropic medication knowledge test 
(t = 0.250; p = 0.813)
•	 At	baseline,	all	participants	
strongly agreed with the state‐
ments “I know enough about my 
medication” and “Medication is 
an important part of my treat‐
ment.” There were few differ‐
ences in the self‐report measures 
post‐intervention
• 5 out of 6 participants “strongly 
agreed” they had met their per‐
sonal objectives by attending the 
group, the remaining participant 
was “not sure”
Walmsley 
et al., 
2016
Qualitative 
study
To explore how 
the reproduc‐
tive capacity 
of women with 
intellectual 
disabilities is 
managed and 
the associated 
processes of 
contraceptive 
decision making
N = 19; women with 
intellectual dis‐
abilities who were 
users of specialist 
intellectual dis‐
ability services and 
using, intending 
to use or had used 
contraception
Face‐to‐face interviews were 
conducted using a question‐
naire in easy‐read format 
with illustrations
• Several participants had no 
understanding of contraception 
as a means to prevent pregnancy ‐ 
only 2 were well informed
• Few women had made an in‐
formed choice about the type of 
contraceptive to use
• Most reported the decision being 
made for them
• Several women reported that the 
contraception prescribed to man‐
age periods was ineffective
TA B L E  2   Continued
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3.3.3 | Decision making
Only two studies presented information about the decision to take 
medication. The case study participant in Flood and Henman (2015) 
stated that he took his tablets because he did not “want to die,” 
suggesting that he understood the purpose of the medication and 
could use this to make a decision about whether to take it. Most 
participants in Walmsley et al. (2016) reported having the decision 
to use contraception made for them, with the exception of two 
women who appeared to be making proactive decisions about their 
contraception.
3.3.4 | Factors affecting medication knowledge
One study compared medication knowledge between patients 
with intellectual disabilities with and without capacity and found 
that medication knowledge was generally better for those pa‐
tients with intellectual disabilities who had capacity (Huneke et 
al., 2012). Capacity was defined as having the capacity to consent 
for	medical	treatment	and	was	based	on	staff	report.	All	partici‐
pants without capacity demonstrated poor knowledge in all areas 
(name and purpose of medication, dose schedule, and duration of 
treatment, advantages and potential disadvantages of treatment, 
consequences of not taking medication and contraindicated foods 
and drinks). Participants with capacity demonstrated good knowl‐
edge (i.e., defined by the authors as above 50% based on past 
publications	 (Arscott,	 Stenfert	 Kroese,	 &	 Dagnan,	 2000;	 Barat,	
Andreasen,	 &	 Damsgaard,	 2001))	 of	 advantages	 of	 treatment,	
dose schedule, purpose of the medication and consequences of 
not taking the medication. Knowledge of the duration of treat‐
ment and the names of medications were rated as poor for those 
with capacity.
3.4 | Understanding of prescription medication risks
In comparison with general knowledge of prescription medica‐
tion, the included articles presented little information regard‐
ing	 participants	 with	 intellectual	 disabilities’	 understanding	 of	
medication risks. Overall, participants were often confused or 
unaware of adverse effects associated with their prescription 
medication.
3.4.1 | Risks of taking multiple medications
Beacroft and Dodd (2010) found that the majority of participants 
(70%) said that they would take medication when in pain. However, 
when the remaining participants were asked why they would not 
take medication, they expressed confusion and concern about 
whether the pain medication would react negatively with their regu‐
lar medication. It is not clear, however, whether the 70%, who said 
they would take their medication as a result of being in pain, had an 
understanding of the risks of taking their prescription medication, 
including potential reactions with other medication.
3.4.2 | Adverse effects
Three studies discussed participant's understanding of adverse ef‐
fects of prescription medication, two of which found largely poor 
knowledge	about	disadvantages	or	adverse	effects.	All	participants	
in	Huneke	et	al.’s	(2012)	study	demonstrated	poor	knowledge	of	the	
possible disadvantages of their medication. However, those with ca‐
pacity showed very good knowledge on contraindicated foods and 
drinks. In Davis et al. (2016), the majority of participants seemed 
unaware of the adverse effects that could result from their asthma 
medication, although some participants were able to express some 
physiological undesirable effects of their inhaler, for example, “I had 
a bad reaction…my legs were shaking, my arms were shaking.”
The	 participant	 in	 Flood	 and	 Henman’s	 (2015)	 case	 study	 ap‐
peared to have some knowledge of adverse effects. When dis‐
cussing his medication with the researcher, he stated he knew that 
diarrhoea was a side effect of two of his medications. However, po‐
tential adverse effects of his other medications were not discussed 
so it cannot be concluded whether he had knowledge of the adverse 
effects of all his medication.
3.4.3 | Lack of information about risks
Two studies indicated that some people with intellectual disabili‐
ties recognized that they did not understand enough about the 
adverse effects and risks of their prescription medications, and 
expressed the desire for more information. Only one respondent 
in	Fish	et	al.’s	questionnaire	study	(2017)	stated	that	the	pharma‐
cist mentioned an adverse effect of their medication, and four 
people (7%) expressed the need for information about adverse 
effects and risks in order for them to make a decision about medi‐
cines. Participants were asked to provide suggestions for improve‐
ment on the psychotropic medication education group reported 
by Sheehan et al. (2017); one participant stated they “wanted to 
know more about side effects.”
3.5 | How to improve knowledge of prescription 
medication in people with intellectual disabilities
Eight out of ten articles in this scoping review reported ways in which 
knowledge of prescription medication amongst people with intellec‐
tual disabilities could be improved. It was commonly suggested, that 
a wide array of sources of information should be readily available 
for people with intellectual disabilities including easy‐read leaflets 
with pictures and/or diagrams and media platforms such as YouTube.
3.5.1 | Format of information
Four of the included studies discussed how medication informa‐
tion	is	presented	to	people	with	intellectual	disabilities.	Davis	et	al.’s	
qualitative study (2016) found that the way in which information was 
conveyed to people with intellectual disabilities using inhaled asthma 
medications was crucial. Written information was often reported to 
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be a challenge to understand, for example, one participant stated “it 
would	be	hard	for	me	to	read	because	I’m	almost	blind	in	one	eye	and	
I read things back to front.” Some participants reported turning to 
media platforms, such as YouTube, to find out information regarding 
their medication (Davis et al., 2016).
Extending this, Fish et al. (2017) found that people would like 
information presented in ways other than verbally, that is, photos/
videos of how to use their medication (n = 3), mobile alerts/spe‐
cial alarm as a reminder/timetable (n = 4). They also expressed how 
aids such as hearing loops/braille/sign language and/or interpreters 
should be utilized when appropriate (n = 5).
Easy‐read and pictorial support was specifically mentioned in 
two of the articles. Walmsley et al. (2016) suggested using illustrated 
and easy‐read information to help improve practice when explaining 
contraception to people with intellectual disabilities and in Fish et al. 
(2017), 66% (n = 38) of people with intellectual disabilities wanted 
an easy‐read leaflet and 17% (n = 10) wanted pictures or diagrams to 
help understand their medicine.
These findings around the use of different formats of informa‐
tion	were	 also	 echoed	 by	 clinicians.	When	 exploring	 the	 doctors’	
comments during clinic attendance, Davis et al. (2014) also found 
suggestions for the use of non‐verbal information when trying to 
increase the knowledge of prescription medication in people with 
intellectual disabilities, for example, “some pictures should be given; 
copies should be shared between [community organisation] and his 
parents.”
3.5.2 | Educating people with intellectual disabilities
Alongside	tailoring	medication	 information	to	the	person	with	 in‐
tellectual	disabilities’	needs,	the	included	studies	also	emphasized	
the importance of clinicians checking the person's understanding 
of what is required and/or what support is available when using 
the medication (Davis et al., 2016; Fish et al., 2017; Walmsley et 
al., 2016). Two studies conducted interventions to educate people 
with intellectual disabilities about their medications. Participants 
in Ferguson and Murphy's study (2014) received discussion‐based 
group training sessions tailored to their medications (haloperidol, 
metformin and sodium valproate). Participants completed ques‐
tionnaires before the training sessions and two weeks after their 
final training session to measure the effect of the training and a 
significant	difference	between	A‐ACQ	scores	at	baseline	and	post‐
intervention was found. Improvements were associated with ver‐
bal comprehension, suggesting that those with verbal abilities may 
benefit more from training. However, not all items on the ques‐
tionnaire directly asked about medication knowledge, therefore 
making it difficult to draw specific conclusions about medication 
knowledge.
Participants in Sheehan et al. (2017) also took part in an inter‐
vention aiming to educate people with intellectual disabilities about 
their medication. Participants completed a psychotropic medi‐
cation knowledge test before and after the education group. The 
pre‐ and post‐test scores were similar, and there was no statistically 
significant difference, suggesting that the intervention was not ef‐
fective at increasing medication knowledge.
3.5.3 | Training health professionals
As	well	as	educating	people	with	intellectual	disabilities	about	their	
medication, five studies found that it is also important to train and 
educate health professionals in providing information to people with 
intellectual disabilities. It was identified that respiratory physicians, 
asthma educators, GPs and pharmacists are important in training in‐
haler use in people with intellectual disabilities (Davis et al., 2014). 
Doctors’	notes	emphasized	the	need	for	staff	knowledge	and	train‐
ing “please make sure staff are aware of how to use the puffers with 
spacer,” “buy spacer and teach him” to help people with intellectual 
disabilities understand how to use their medication.
Fish et al. (2017) explored the level of information regarding 
medication, provided by both GPs and pharmacists from the per‐
spective of people with intellectual disabilities. Fifty‐five per cent 
of participants (n = 32) commented on receiving helpful information 
which helped their understanding of medication from their GP such 
as “showed how to use the medication,” “told everything about my 
medicine,” “I have a good doctor who will tell me what the medicine 
is for and will answer any questions I have.” However, 29% of par‐
ticipants (n = 17) felt the information from their GP was not helpful 
due to information not being accessible/understandable (n = 7), only 
being provided with basic information (n = 6) or the information only 
being given to their carer (n = 2). In two cases, no information was 
provided by their GP, for example, “I just get a prescription” and 24% 
(n = 14) of participants reported receiving no information about their 
medication at all from their pharmacist. This suggests a training need 
for professionals about how to best provide information to people 
with intellectual disabilities.
As	well	as	training	and	educating	staff	and	medical	professionals	
on an individual basis, one study exploring the use of diabetes med‐
ication in people with intellectual disabilities suggested the need 
for groups to work together. Flood and Henman (2015) discussed 
the need to provide person‐centred accessible information and sug‐
gested how pharmacists could, where appropriate, put people with 
intellectual disabilities in touch with “expert” peers for education 
and support and to encourage engagement with other healthcare 
professionals involved in their care.
Walmsley et al. (2016) also suggested involving a third party, 
that is, carer or family member if the person with intellectual dis‐
abilities indicates this might be helpful. However, Davis et al. (2016) 
and Fish et al. (2017) highlighted that it is important for healthcare 
professionals to talk directly to the person with intellectual dis‐
abilities, when appropriate, rather than talking to the carer or sup‐
port worker. Two participants in Fish et al. (2017) commented on 
information being given to their carer by GPs and five stated that 
their	 pharmacist	 speaks	 to	 their	 carer	 instead	of	 them.	Although	
10 respondents wanted their support workers/families involved 
and informed, four participants expressed a preference for the in‐
formation being explained to them rather than their carer. Davis 
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et al. (2016) revealed the frustration experienced by people with 
intellectual disabilities when doctors talked to the caregiver rather 
than directly to them, which affects their understanding of their 
medication “I always have to ask [name of carer] cause the doctors 
explain it to her.”
4  | DISCUSSION
4.1 | Main findings
The aim of this scoping review was to identify and analyse studies 
that explored the understanding that people with intellectual dis‐
abilities have of their prescribed medication, with a focus on the 
risks of adverse effects, and how to improve their medication un‐
derstanding. From the 1,326 articles initially extracted from various 
databases, 10 studies met the inclusion criteria.
This scoping review brings together findings from studies rel‐
evant to current policy and practice regarding medication use in 
people with intellectual disabilities. Overall, these studies suggest 
that many people with intellectual disabilities do not fully under‐
stand their prescription medication, including a lack of knowledge 
about medication names, how to take their medication and the 
associated risks (Beacroft & Dodd, 2010; Davis et al., 2016, 2014; 
Fish et al., 2017; Huneke et al., 2012; Walmsley et al., 2016). Some 
studies suggested that people with intellectual disabilities are more 
likely to understand the purpose of their prescription medication 
than the potential disadvantages and adverse effects (Davis et al., 
2016; Huneke et al., 2012). Some studies showed some people with 
intellectual disabilities were well informed about their medication 
(Ferguson & Murphy, 2014; Sheehan et al., 2017; Walmsley et al., 
2016), and this could be related to better verbal abilities (Ferguson 
& Murphy, 2014).
Legally, it is required that all patients with mental capacity, in‐
cluding people with intellectual disabilities, should be effectively 
informed about the risks of their medicines and should receive in‐
formation in an accessible format for them to help them make de‐
cisions about their treatment (Montgomery v Lanarkshire Health 
Board (Scotland) 2015; NHS England, 2016). However, this review 
suggests that people with intellectual disabilities, including those 
with capacity, often have a lack of understanding about the risks of 
medication, including confusion about potential reactions with other 
medications (Beacroft & Dodd, 2010) and lack of knowledge of ad‐
verse effects (Davis et al., 2016; Huneke et al., 2012).
4.2 | Implications
4.2.1 | Accessibility and delivery of information
Guidelines for healthcare professionals outline the importance of 
patient involvement in the decision‐making process and encourage 
effective communication directly with the patient (NICE, 2012), and 
the	AIS	(NHS	England,	2016)	specifies	the	responsibility	of	services	
to make information understandable and accessible to everyone. 
Therefore, when involving people with intellectual disabilities in the 
decision‐making process, it is essential to ensure the information 
being	 communicated	 is	 understandable	 and	 accessible	 (Adams	 &	
Carr, 2017). However, this review suggests that people with intellec‐
tual disabilities are not always receiving accessible information about 
their medication directly from healthcare professionals (Davis et al., 
2016;	 Fish	 et	 al.,	 2017;	 Flood	&	Henman,	2015).	Although	people	
with intellectual disabilities often want their carers or family mem‐
bers to be informed about their medications and to be present dur‐
ing the consultation, they express frustration when the healthcare 
professional directs the information solely to the caregiver (Davis et 
al., 2016; Fish et al., 2017).
General recommendations for effective health promotion includes 
educating and empowering people with intellectual disabilities (Marks 
& Heller, 2003). The findings from this scoping review suggest that 
these recommendations apply to consultations regarding medications 
and that further training may be needed to support healthcare pro‐
fessionals to directly engage people with intellectual disabilities about 
their medications and make reasonable adjustments to support them. 
Promoting	awareness	of	the	AIS	amongst	people	with	intellectual	dis‐
abilities and their carers may also help them to let their healthcare 
professional know when they would prefer different formats of infor‐
mation. Through the Disability Partnership project (Mencap, 2016), 
accessible resources have been produced for people with intellectual 
disabilities, carers and pharmacists to support them with medications 
and help achieve greater empowerment.
Risks associated with non‐prescription medicines and comple‐
mentary treatments are beyond the scope of this review although 
consideration should be given to the interactions between non‐pre‐
scription medicines and prescription medicines, which can lead to 
harm and potential relapse. It should be noted that non‐prescription 
medicines can be bought in retail outlets, petrol stations and over 
the Internet where there are no pharmacists or doctors on site to 
provide advice.
4.2.2 | Education for people with intellectual 
disabilities
It is important to consider what can be done to ensure people with 
intellectual disabilities are supported to access and understand in‐
formation regarding their medication, and risks of adverse effects. 
Ferguson and Murphy (2014) found that training sessions to improve 
medication	understanding	significantly	improved	participants’	capac‐
ity in relation to medication taking. This is promising and illustrates 
that people with intellectual disabilities can be supported to improve 
their understanding of their medication and be involved in decisions 
about	their	treatment.	In	contrast,	Sheehan	et	al.’s	(2017)	education	
group intervention did not have an effect on medication knowledge. 
Participants	in	Sheehan	et	al.’s	study,	however,	were	believed	by	the	
authors to overestimate their knowledge and skills at baseline and 
consequently any improvements were difficult to determine.
In order to promote medication understanding, it is important 
to take into account the needs of the individual and to provide 
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information in the most accessible way, which may include using pic‐
tures/diagrams, easy‐read text, audio, video and braille (Fish et al., 
2017; Simpson & Douglas, 2011; Strydom et al., 2001; The Disability 
Partnership, 2016). This places a particular emphasis on the avail‐
ability, or creation, of appropriate resources. However, patient infor‐
mation leaflets supplied with dispensed medicines from pharmacies 
can be difficult to understand (Davis, Wolf, Bass, Middlebrooks, et 
al., 2006; Davis, Wolf, Bass, Thompson, et al., 2006). Easy‐read med‐
ication leaflets are freely available on the Internet, but are of vari‐
able	quality	and	often	not	updated	for	many	years	(Adams	&	Shah,	
2016a, 2016b), meaning that healthcare professionals and/or carers 
may need to adapt more general resources about taking medica‐
tions	to	meet	the	person	with	intellectual	disabilities’	needs	(Hollins,	
Carpenter, Bradley, & Egerton, 2017; The Disability Partnership, 
2016). Group education aimed at specific conditions may also be ap‐
propriate for some people with intellectual disabilities (Ferguson & 
Murphy, 2014), and in some areas, this could be embedded through 
workshops run by community learning disability teams.
4.3 | Strengths and limitations
One of the strengths of this scoping review was the use of the 
five‐stage	 framework	 (Arksey	&	O'Malley,	2005),	which	allows	 for	
transparency	and	reproducibility.	Another	strength	is	the	use	of	two	
researchers who independently identified and screened the data 
and the introduction of a third researcher who was consulted in the 
case of disagreements. Nine out of the ten studies included within 
this review collected data from the people with intellectual disabili‐
ties themselves. This is important as information from a secondary 
source such as a carer or support worker may not always accurately 
reflect the views of people with intellectual disabilities.
Several limitations to this scoping review should also be acknowl‐
edged. Firstly, articles were only included if published between 2011 
and 2017. This approach was taken to focus on current practice, but it 
is acknowledged that studies prior to 2011 may also offer additional in‐
sights. In the majority of studies, the main aim was not to explore partic‐
ipants	with	intellectual	disabilities’	knowledge	of	medication;	therefore,	
some of the findings reported here are only reflective of a relatively small 
aspect of the original paper. The majority of the studies were conducted 
in the UK, and so due to differing policy and practice contexts, these 
findings	may	not	generalize	to	other	countries.	Also,	some	of	the	studies	
had limited sample sizes; for example, Dysch et al. (2012) included four 
participants and Sheehan et al. (2017) included six participants, and so 
applying findings to the rest of the population with intellectual disabili‐
ties could be problematic. Often the language used in the paper's anal‐
yses, for example, “some” of the sample, made it difficult to understand 
the number of participants whom expressed a particular view.
5  | CONCLUSIONS
Currently, research regarding the understanding of prescription medi‐
cations in the intellectual disability population is sparse. This scoping 
review	identified	10	studies	addressing	this	 issue.	Although	levels	of	
knowledge about different aspects of medication use varied, often 
participants had poor knowledge of their medication, how to use it 
and what the risks of adverse effects were. The level of knowledge 
and information provision practices described here is unlikely to meet 
the guidelines currently in place. This review has indicated recommen‐
dations for promoting medication understanding based on empirical 
research, and future research should evaluate how best to improve 
medication understanding in people with intellectual disabilities.
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